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Abstract: Liver fat accumulation is an important pathophysiological feature of non-alcoholic fatty
liver disease that may be modulated by dietary supplements (DS). A systematic search of the literature
was conducted for randomized controlled trials (RCTs) pertaining to the effect of a DS on liver fat as
assessed using quantitative tomographic imaging in human adults. Where feasible, data were pooled,
and meta-analyses conducted using random-effect model. Quality assessment was done according the
Cochrane Collaboration’s tool for assessing risk of bias. Twenty RCTs, involving 1171 overweight and
obese adults, of which 36% were females, with or without comorbidities, were included. Only RCTs
assessing omega-3 fatty acids (n = 4) and resveratrol (n = 4) qualified for meta-analysis. Results did
neither favor omega-3 (effect size −1.17; weighted mean difference (WMD) (95% confidence interval
(CI)) −3.62, 1.28; p < 0.001) nor resveratrol supplementation (0.18; 95% CI −1.08, 1.43; p = 0.27). The
findings of the qualitatively summarized RCTs suggested that catechins (n = 1), Lactobacillus reuteri
(n = 1), and carnitine (n = 1) may reduce liver fat. All other DS did not show any influence. The
current evidence is scarce, of limited quality and does not support DS use to reduce liver fat. Further
well-designed trials are warranted.
Keywords: liver fat; non/alcoholic fatty liver disease; dietary supplements; magnetic resonance
imaging; magnetic resonance spectroscopy; computed tomography
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world and
ranges from isolated steatosis to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis,
increasing the risk of cirrhosis and hepatocellular carcinoma [1]. The accumulation of liver fat (LF), that
characterizes hepatic steatosis, is a key feature of the complex pathophysiology underlying NAFLD.
Important factors are an increased influx of fatty acids from the diet and peripheral fat stores as well as
upregulated de novo lipogenesis [2]. Hepatic steatosis is defined as LF of at least 5% of liver weight or
5% of hepatocytes containing lipid vacuoles. Whilst liver biopsy is considered as the gold standard
method to quantify LF content [3,4], its invasiveness limits its applicability. Imaging modalities such
as computed tomography (CT), magnetic resonance imaging-proton density fat fraction (MRI-PDFF),
and magnetic resonance spectroscopy (MRS) are considered acceptable alternatives to quantify LF.
Nutrients 2020, 12, 2302; doi:10.3390/nu12082302 www.mdpi.com/journal/nutrients
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
5
7
0
2
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Nutrients 2020, 12, 2302 2 of 14
Lifestyle modifications, including energy restriction and physical activity, represent the cornerstone
for the prevention and treatment of LF accumulation by inducing weight loss [5], improving insulin
sensitivity and reducing inflammation [2,6–8]. However, the use of dietary supplements (DS) may
further contribute to improve hepatic lipid homeostasis.
DS are a concentrated source of nutrients and other bioactive compounds that are intended to
supplement the diet [9] comprising specific macro- and micronutrients, phytochemicals, dietary fibers,
as well as probiotics and medicinal mushrooms [10,11]. Several studies have explored the efficacy
of different DS on LF in humans in various populations (e.g., children and adults), as stand-alone
or combined interventions (e.g., physical exercise [12] and drugs [13]). Despite the great interest
in this area, no systematic effort on summarizing and quantifying the evidence on this topic has
been undertaken.
Therefore, the objective of this study was to summarize the available evidence and evaluate the
efficacy of various DS on LF in randomized clinical trials with adults using CT, MRI-PDFF, or MRS.
2. Materials and Methods
2.1. Data Sources and Search Strategy
This review followed the guidelines of a recently published paper on how to perform a systematic
review and meta-analysis [14], and is reported in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement. By using terms related to DS and liver fat,
an information specialist (B.M.) searched five bibliographic databases (Embase.com, Medline Ovid,
PubMed, Cochrane CENTRAL, Web of Science, and Google Scholar) before 6 May 2020 (Supplementary
Materials Table S1).
2.2. Study Selection and Eligibility Criteria
Studies were included if they met the following inclusion criteria: (i) were randomized controlled
trials (RCTs); (ii) were performed on outpatient adults of ≥ 18 years; (iii) included an intervention that
comprised of DS assessing its independent effect (e.g., combined interventions such as DS and physical
activity were not considered eligible) and a control arm; (iv) reported a change from baseline to end of
study in LF measured by tomographic imaging (MRI-PDFF, MRS, or CT); and (v) the interval between
the assessment was ≥ 24 h (in order to avoid missing any potential short-term effects of DS [15,16]).
Two independent reviewers (B.K. and A.V.) screened the titles and abstract in the first round, and the
full text in a second round.
2.3. Data Extraction
The two reviewers independently performed data extraction using a standardized protocol
(PROSPERO number CRD42020153556) and predesigned form including relevant information on
lead author, study location, study design, study participants characteristics (health status, age,
body mass index), DS (intervention characteristics and duration), control characteristics, and LF
assessment. In case of incomplete data, corresponding authors were contacted via email.
2.4. Assessing the Risk of Bias
The two reviewers independently evaluated risk of bias within each individual RCT using the
Cochrane Collaboration’s tool [17]. A detailed assessment of the risk of bias can be found in the
Supplementary Materials Table S2.
2.5. Data Synthesis and Analysis
The effect of the DS was defined as the difference between DS-induced vs. control-induced change
in LF. In order to standardize the numerical values from all RCTs, the method by Hozo et al. [18]
was used to calculate mean and standard deviations, when feasible. Random-effect models were
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used to obtain estimates of weighted mean differences and 95% confidence intervals. As sensitivity
analysis, we showed results of fixed effect models in the forest plots. Heterogeneity was assessed
using the Cochrane χ2 statistic and the I2 statistic and was determined as low (I2 ≤ 25%), moderate
(25% < I2 < 75%), or high (I2 ≥ 75%) [19]. All statistical analyses were conducted with STATA, Release
14 (Stata Corp, College Station, TX, USA). The trials that could not be quantitatively pooled were
summarized qualitatively (n = 12).
3. Results
The bibliographic searches identified 2995 unique abstracts (Figure 1).
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Figure 1. PRISMA flowchart showing the process for the inclusion of studies. Abbreviations:
DS = dietary supplements, n = number of randomized controlled trials, PRISMA = Preferred Reporting
Items for Systematic Reviews and Meta-Analyses.
After screening for titles and abstracts, 110 articles ere considered for full-text assessment,
of which 20 RCTs were eligible for the final analysis. Among those, eight trials contributed to the
meta-analysis and 12 were included in the qualitative review.
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3.1. Characteristics of RCTs
A summary of the most important characteristics of the 20 RCTs, based on 1171 patients of which
36% were female, can be found in Table 1. More detailed characteristics of each study are found in
Supplementary Materials Table S3.
Table 1. Characteristics of randomized controlled trials by dietary supplements.
Omega-3 Phytochemicals (Incl.Resveratrol) Probiotics Vitamins
Amino Acid
Derivatives
Number of RCTs 4 8 4 3 1
Location
Europe 3 4 1 3 -
Asia - 2 2 - 1
Australia 1 1 - - -
North America - 1 - - -
South America - - 1 - -
Demographics and
anthropometrics
Total participants (n) 375 369 231 138 72
Age (yrs) 52 (10.9) 1 49 (9.9) 1 49.7 (11.6) 1 53 (8.3) 1 51 (9.2) 1
BMI (kg/m2) 31.6 (6.2) 1 31.6 (3.6) 1 32.5 (4.8) 1,2 33 (3.5) 1 27.5 (3.2) 1
% women 40 36 38 35 31
Specific restricted study
population 3
NAFLD 3 5 1 1 4 1 4
NASH - - 2 - -
PCOS 1 - - - -
Prediabetic - 1 - - -
Insulin-resistant - 2 - - -
T2DM - - - 1 4 1 4
Others 1 - 1 2 -
Duration (weeks) 12–78 8–26 4–61 12–26 12
Liver fat measured by
MRS 3 6 2 2 -
MRI - - - 1 -
MRI-PDFF 2 1 1 - -
CT - 1 1 - 1
1 Results are reported in mean (standard deviation (SD)). 2 Only three studies included in the calculation.
3 This column only serves as a simple overview of the different populations. Obviously, many of the
diseases overlap. More detailed information and how the diseases are defined can be found in Table
S3 in the Supplement. 4 Study exclusively included a population with diagnosed NAFLD and T2DM.
Abbreviations: BMI = body mass index, CT = computed tomography, MRI = magnetic resonance imagery,
MRS = magnetic resonance spectroscopy, NAFLD = non-alcoholic fatty liver disease, n = number of participants,
NASH = non-alcoholic steatohepatitis, PCOS = polycystic ovary syndrome, PDFF = proton density fat fraction,
RCTs = randomized controlled trials, T2DM = type 2 diabetes mellitus, yrs = years.
Eleven RCTs were performed in Europe, five in Asia, two in Australia, and one each in North and
South America. No RCT studied normal-weight volunteers and all were performed in overweight
and obese patients: one RCT included women with polycystic ovary syndrome (PCOS) and two RCTs
studied non-alcoholic steatohepatitis (NASH) patients. Of the 11 RCTs studying NAFLD patients,
two of them studied patients with type 2 diabetes mellitus (T2DM) and three with prediabetes or
insulin resistance. Two RCTs studied exclusively overweight men without any other comorbidities,
one RCT studied obese patients deficient in vitamin D (VD) and another RCT with prediabetes.
Concerning the intervention, the DS were divided into the following categories: n-3 polyunsaturated
fatty acids (n = 4; omega-3), phytochemicals (n = 8; 4 resveratrol, 1 pinitol, 1 catechins, and 2
resistant starches), probiotics and medicinal mushrooms (n = 4; 1 Lactobacillus reuteri, 1 Lactobacillus spp.
plus Bifidobacterium bifidum, 1 Bifidobacterium animalis, and 1 Cordyceps militaris), vitamins (n = 3;
2 vitamin D, 1 nicotinamide riboside), and amino acid derivatives (n = 1; carnitine). The comparator
entailed olive oil (n = 3), micro-cellulose (n = 1), amylopectin (n = 2), maltodextrin (n = 1), and inert
substances, i.e., placebo (n = 11). Two RCTs only used lifestyle recommendation as a comparator.
Nutrients 2020, 12, 2302 5 of 14
The duration of the interventions ranged between 4–78 weeks. Regarding the different methods of LF
quantification, 12 RCTs used MRS, five RCTs used MRI-PDFF, and three RCTs used CT.
Figure 2 graphically illustrates key findings of the analysis. A descriptive summary of the
qualitatively assessed RCTs are provided in Table 2 and a more detailed numerical analysis in
Supplementary Materials Table S4.
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Figure 2. Summary of the most important findings. Each circle represents a study included in
the analysis. Green circles indicate positive (reduction in liver fat compared to control) findings
whereas orange circles denote negative findings (no significant difference between intervention
and control). Abbreviations: DHA = docosapentanoic acid, NALFD = non-alcoholic fatty liver disease,
NASH = non-alcoholic steatohepatitis, N/A = non-available. 1 Statistically significant reduction in liver
fat content was reported in the intervention group. No change in liver fat was observed in the control
group (p-value for the between group difference was not reported; detailed results in Supplementary
Materials Table S4).
Table 2. Descriptive summary of the 12 randomized controlled trials that were analyzed qualitatively,
investigating the associations between dietary supplements and liver fat.
Lead Author,
Publication Year
Treatment Characteristics
Main Findings 1
Dietary Supplement Control Duration
Phytochemicals
Lee et al., 2019 Pinitol, 300 mg or 500 mg Placebo 12 weeks
Although there were no significant differences among
the treatment groups in the LF content changes using
MRI-PDFF, LF content decreased significantly in the
low-dose group (p = 0.01), whereas no significant change
was detected with the higher pinitol dose.1
Sakata et al., 2013 Catechins, 200 mg or 1080 mg Placebo 12 weeks
The improvement in liver-to-spleen CT attenuation was
11.3% (2.8%) in the high density and −6.1% (12.1%) in
the low-density intervention groups vs. −3.3% (8.5%) in
the placebo group. Compared to control group, the
difference was −2.8% (7.4%) for the low-dose and 14.6%
(6.5%), p < 0.05 for the high-dose intervention group.
Johnston et al., 2010 Hi-Maize 260, 40,000 mg Amioca 12 weeks
LF fat reduction was −1.7% (7.3%) in the intervention vs.
−0.3% (4.5%) in the control group. The between group
difference was 1.4% (4.6%) (p = n.s.), measured by MRS.
Peterson et al., 2018 Hi-Maize 260, 45,000 mg Amioca 12 weeks
MRS measurements could not show any significant
decrease in LF neither in the intervention 0.2% (6.6%)
nor in the control group 1.6% (6.7%) and between both
groups −1.3% (4.0%), p = 0.23.
Probiotics and medicinal mushrooms
Ferolla et al., 2016 Synbiotic (Lactobaccillus reuteri),0.1 × 109 CFU Usual diet 13 weeks
LF, measured by MRI-PDFF, decreased by −2.5% (4.5%)
in the intervention (p = 0.03) and by 3.0% (5.5%) in the
control group (p = 0.15). The between group difference
was 5.5% (3.3%) (p-value not reported).
Scorletti et al., 2020
Synbiotic (Bifidobacterium
animalis (subspecies lactis
BB-12)), 1.0 × 109 CFU
Maltodextrin,
8000 mg
44–61
weeks
LF, measured by MRS, changed by −3.8% (4.3%) in the
intervention and by −6.1% (4.0%) in the control group.
No significant between group difference was detected
2.3% (2.6%), p = 0.30.
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Table 2. Cont.
Lead Author,
Publication Year
Treatment Characteristics
Main Findings 1
Dietary Supplement Control Duration
Wong et al., 2013
Probiotics (Lactobaccillus
plantarum, L. delbrueckii spp.
bulgaricus, L. acidophilus, L.
rhamnosus; Bifidobacterium
bifidum), 0.2 × 109 CFU
Usual diet 26 weeks
LF, measured by MRS, decreased significantly in the
intervention −7.7% (9.8%), p = 0.03, and remained static
in the control group at −0.9% (4.9%), p = 0.15. No
significant change between the groups was detected
(between group difference −6.8% (2.0%), p = 0.07).
Heo et al., 2015 Ascomycetes (Cordycepsmilitaris), 1500 mg Placebo 4 weeks
In analysis of the liver CT scan the mean ratio of change
of Hounsfield increased by an average of 21.4% (45.1%;
mean (SEM)) in the intervention group and 9.6% (11.4%;
mean (SEM)) in the control group (p = 0.10).
Vitamins
Barchetta et al., 2016 Vitamin D, 2000 IU Placebo 24 weeks
Changes in LF, measured by MRI, of −0.4% (2.1%) in the
intervention and of −0.7% (1.5%) in the control group,
did not differ significantly between both groups 0.3%
(1.3%; p = 0.57).
Wamberg et al., 2011 Vitamin D, 7000 IU Placebo 26 weeks
LF, assessed by MRS as the arbitrary lipid:water ratio,
changed by 0.05% (0.07%), p = 0.11 in the intervention
group and by 0.00% (0.06%), p = 0.61 in the control
group. The difference between the groups of 0.05%
(0.04%) was not significant (p = 0.51).
Dollerup et al., 2018 Nicotinamide riboside, 2000 mg Placebo 12 weeks
A 2% (2.6%) reduction in LF in the intervention group
was measured by MRS compared to a 0.2% (2.6%)
reduction in the control group. No significant difference
between groups was found −1.8% (1.7%), p = 0.13.
Amino-acid derivatives
Bae et al., 2015 Carnitine-orotate, 2472 mg Placebo 12 weeks
On the hepatic CT analysis, mean changes in
liver-to-spleen attenuation ratio were 6.2% (9.0%), p <
0.01 in the intervention group and 0.7% (8.1%), p = 0.58
in the control group. These results showed a significant
difference in LF reduction between both groups 5.5%
(5.4%), p = 0.01.
If available, results are reported in mean (SD). In case of other values, they are mentioned directly in the text. 1
Authors reported results graphically only. The data of this article was extracted from the box-plot graphic with the
program Plot Digitizer and can be found in Table S4 in the Supplement. CFU = colony forming units, CT = computed
tomography, LF = liver fat, MRI = magnetic resonance imagery, MRS = magnetic resonance spectroscopy, n.s. =
non-significant, PDFF = proton density fat fraction, SD = standard deviation, SEM = standard error of the mean.
3.1.1. Omega-3
We identified four RCTs [20–23] investigating the efficacy of omega-3 (combination of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) using MRS (n = 2) or MRI-PDFF
(n = 2) in a total of 375 patients. Scorletti et al. [20] examined the effect of daily dose of 3360 mg of
omega-3 vs. 2400 mg of olive oil over 60 to 78 weeks using MRS in 103 subjects with NAFLD and features
of the metabolic syndrome. Parker et al. [21] studied 50 overweight males without comorbidities for
12 weeks with 2000 mg of omega-3 vs. 2000 mg of olive oil using MRS. Oscarsson et al. [22] studied
the effects of daily 4000 mg of omega-3 vs. placebo using MRI-PDFF in 46 overweight adults NAFLD
and hypertriglyceridemia over 12 weeks. Tobin et al. [23] included 176 adults with NAFLD and
measured the effects of a daily dosage of 2520 mg of omega-3 vs. 3000 mg of olive oil using MRI-PDFF.
When pooling together the findings from those four RCTs, the calculated weighted mean difference
(WMD) was −1.17 with a 95% confidence interval (CI) of −3.62 to 1.28. Heterogeneity was high with
an I2 = 84.7%, p < 0.001 (Figure 3).
Due to differences in LF assessment among the four RCTs, we performed a separate analysis
pooling together RCTs which assessed the LF content using MRI-PDFF and MRS respectively and
results remained in line with the overall observation (Supplementary Materials Figure S1).
Nutrients 2020, 12, 2302 7 of 14
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Figure 3. Meta-analysis of the effect of omega-3 and resveratrol supplementation on liver fat using
a random-effects model. Abbreviati ns: CI = co fidence interval, DHA = doc sahexaenoic acid,
DPA = docosapentaenoic acid, EPA = eicosapentaenoic acid, MRI = magnetic resonance imaging,
MRS = magnetic resonance spectroscopy, NAFLD = non-alcoholic fatty liver disease, WMD = weighted
mean difference.
3.1.2. Phytochemicals
Out of the eight RCTs [24–31] assessing phytochemicals, four RCTs qualified for qualitative
analysis only and used the DS pinitol [28], catechins [29], and resistant starches [30,31]. The other four
RCTs [24–27], assessing the efficacy of resveratrol using MRS in a total of 174 patients, were included
in a meta-analysis. Chachay et al. [24], Heebøll et al. [25], and Poulsen et al. [27] studied patients
with NAFLD. Kantartzis et al. [26] studied insulin resistant patients. The daily doses of resveratrol
supplementation were 3000 mg for 8 weeks vs. micro-cellulose [24], 1500 mg for 26 weeks vs.
placebo [25,27] or 150 mg for 12 weeks vs. placebo [26]. None of the RCTs demonstrated a significant
change in LF content and this was in line with the pooled estimated of our meta-analysis (WMD 0.18;
95% CI −1.08, 1.43). The heterogeneity was low with an I2 of 22%, p = 0.27 (Figure 3).
Among the four RCTs included in qualitative synthesis, besides an indication that low doses of
pinitol and catechins may improve the LF, other phytochemicals did not show beneficial effects on
LF content.
In particular, Lee et al. [28] assessed the effects of a 12 week regimen of 300 mg (low) or 500 mg
(high) of daily pinitol vs. placebo in 90 subjects with NAFLD using MRI-PDFF. Despite a lack of
significant differences among the treatment groups, LF content decreased significantly in the low-dose
group at 12 weeks compared to baseline (p = 0.01), whereas no significant change was detected with
the higher pinitol dose (p-value not reported). Of note, the baseline of LF in the low-dose pinitol group
(20.0 ± 1.5%) was higher than in the high-dose group (14.8 ± 1.9%). Therefore, the potential of the DS
to decrease LF in the low-dose group was greater than in the high high-dose group, which could be an
explanation for the greater decrease in LF in the low-dose group. Such dependence from baseline LF
content was notably also observed with other DS. For instance, Cussons et al. reported that LF decreased
with omega-3 only when individuals started with a higher LF amount (LF percentage >5%) [32].
Sakata et al. [29] contrasted 200 mg (low) or 1080 mg (high) of catechins, a green tea component,
with placebo in 17 NAFLD patients for 12 weeks using CT. The high-dose catechin group significantly
reduced LF as evidenced by an increase in the liver–spleen attenuation, whereas no change in LF
content was observed in the low-dose catechin and placebo group (between group difference high
dose vs. placebo: 14.6% (6.5%), p < 0.05).
In addition, two RCTs [30,31] explored the use of resistant starches (RS) on LF in overweight/obese
adults using MRS. Johnston et al. [30] contrasted a daily intake of Hi-Maize® 260 [33] with Amioca®
in 20 insulin-resistant but normoglycemic adults for 12 weeks and did not find any significant effect
between both groups: 1.4% (4.6%), p = not significant (n.s.).
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Peterson et al. [31] contrasted the same DS with Amioca® over 12 weeks in 68 overweight adults
with prediabetes. Again, there was no statistically significant difference between groups: −1.34% (4.0%),
p = 0.23.
3.1.3. Probiotics and Medicinal Mushrooms
Four RCTs investigated stand-alone probiotics, probiotics combined with prebiotics (synbiotics),
and medicinal mushrooms, of which two in NASH patients [34,35], one in NAFLD patients [36] and one
in patients with elevated liver enzymes [37]. Ferolla et al. [34] compared the effects of Lactobacillus reuteri
(0.1 × 109 CFU/d) combined with dietary fiber (4000 mg) vs. lifestyle recommendations alone over 13
weeks in 50 NASH patients using MRI-PDFF. The intervention group showed a statistically significant
reduction in LF content of −2.5% (4.5%), p = 0.03, whereas LF in the control remained unchanged
(p-value for the between group difference not reported). Scorletti et al. [36] contrasted 1.0 × 109 CFU/d
of Bifidobacterium animalis (subspecies lactis BB-12), combined with fructo-oligosaccharides with
maltodextrin 8000 mg/d in 104 NAFLD patients over 44–61 weeks using MRS. The effect of the synbiotic
vs. placebo did not significantly differ (between group difference 2.3% (2.6%), p = 0.30). Wong et al. [35]
studied 20 NASH patients and assessed the effects of the probiotic mixture Lactobacillus plantarum,
L. delbrueckii spp. bulgaricus, L. acidophilus, L. rhamnosus and Bifidobacterium bifidum (0.2 × 109 CFU/d
over 26 weeks) vs. lifestyle recommendations alone using MRS. Although there was a significant
LF reduction in the intervention group −7.7% (9.8%), p = 0.03, the difference was not statistically
significant between both groups −6.8% (2.0%), p = 0.07. Heo et al. [37] examined the effects of the
ascomycetes Cordyceps militaris (1500 mg/d) vs. placebo in 57 patients over 4 weeks using CT. In both
the intervention and control group, the change in liver-to-spleen attenuation did not significantly differ
from baseline: 21.4% (45.1%) vs. 9.6% (11.4%; both mean (standard error of the mean (SEM))), p = 0.10.
3.1.4. Vitamins
Three RCTs [38–40] examined the effects of vitamin supplementation. Barchetta et al. [38]
investigated the effects of 2000 IU/d of VD vs. placebo in 55 patients with NAFLD and T2DM over 24
weeks using MRI-PDFF. When compared with placebo, VD did not significantly reduce LF at the end of
the trial (0.3% (1.3%), p = 0.57). Wamberg et al. [39] studied VD (7000 IU/d) vs. placebo over 26 weeks
in 43 obese, VD-deficient subjects using MRS. Similarly, VD did not significantly reduce LF when
compared with placebo (0.05% (0.04%), p = 0.51). Dollerup et al. [40] investigated the effects of 2000
mg daily NR, a member of the vitamin B-3 family, vs. placebo over 12 weeks in 40 obese men using
MRS. LF difference between placebo and NR was not statistically significant (−1.8% (1.7%), p = 0.13).
3.1.5. Amino-Acid Derivative
Only one RCT investigated the effects of a DS containing an amino acid derivative. Bae et al. [41]
evaluated daily intake of 2472 mg of carnitine-orotate complex vs. placebo for 12 weeks in 72 diabetic
patients with NAFLD using CT. LF was significantly reduced by carnitine when compared with placebo
(−5.5% (5.4%), p = 0.01), as demonstrated by a significantly greater increase in liver-to-spleen attenuation.
3.2. Further Outcomes and Safety
Only one study reported a significant reduction in body weight in the intervention (Lactobacillus
reuteri) [34] but not in the control group. This study further suggested a LF-reducing effect. A decrease
in liver enzymes was shown in three RCTs [28,29,35] (pinitol, catechins, Lactobacillus spp.) that also
demonstrated a significant decrease in LF. Of the two RCTs [24,41] (omega-3, carnitine) measuring an
increase in liver enzymes, only the carnitine trial was associated with a decrease in LF. None of the two
trials including NASH patients [34,35] reported a significant effect of DS on liver fibrosis. Of the 11 trials
including NAFLD patients only three [20,29,41] showed a beneficial effect of DS on LF (carnitine,
catechins, omega-3). Only the RCT by Heebøll et al. [25] assessing resveratrol reported a serious safety
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event with high likelihood of causality. In this case, febrile leukopenia and thrombocytopenia occurred
after 10 days of resveratrol treatment and returned after repeated exposure.
3.3. Assessment of Bias and Heterogeneity
Summarizing the risk of bias assessment (Supplementary Materials Table S2), four of the RCTs [25,26,38,
41] were rated as good quality RCTs, half (n = 10), were rated as fair quality [21–24,27–29,31,35,40],
and the remaining six RCTs as poor quality [20,30,34,36,37,39]. The most prominent cause for a poor
quality RCT was a lack of allocation concealment or a lack of explanation for how the allocation
was made.
Out of the 20 RCTs included in this systematic review and meta-analysis, two (10%) RCTs [37,39] did
not declare funding source, whereas the remaining 18 RCTs did. Thirteen (55%) RCTs declared receiving
industry funding, of which seven included author-industry ties [21–23,26,36,40,41]. Three (15%) of
RCTs [24,25,27] received funds from private non-industry sources and 11 (55%) RCTs [24–30,34–36,38]
from public grants (Supplementary Materials Table S5).
4. Discussion
In this systematic review and meta-analysis, we summarized the available evidence from 20 RCTs
investigating the effect of various DS on LF using quantitative tomographic imaging in adult populations.
Identified RCTs were performed in overweight and obese people, with different degrees of impaired
glucose homeostasis, mostly diagnosed with NAFLD using different criteria and showed a male
predominance. Our findings do not support the intake of DS to reduce LF in these population.
Our results on omega-3 build upon a prior systematic review and meta-analysis by Parker et al. [42]
assessing the effects of omega-3 on LF and liver function test. In contrast to our findings, Parker et al.
concluded a positive effect of omega-3 on LF and liver function. Their approach differed from ours by
including evidence from observational and intervention studies, stand-alone DS and combination of
DS-diet intervention, and further considering biopsy or ultrasound-based LF assessment methods.
Results from different LF measurements were pooled by Parker et al., whereas we stratified studies by
quantification technique. Four new RCTs have been published since the analysis by Parker at al, which
we have included in our meta-analysis.
Potential beneficial effects of omega-3 on LF include improvement of insulin sensitivity by
decreasing hepatic tumor necrosis factor-α expression, decrease of fatty acid synthesis by negatively
controlling sterol regulatory element binding protein-1c and increase of fatty acid oxidation by
positively controlling peroxisome proliferator-activated receptor-α. Direct mechanistic links have been
mainly shown in animal studies [43–45].
Similarly, positive effects of resveratrol on LF have been mainly proposed by animal studies and
have been attributed to reduction in insulin resistance and improvements in lipid profile [46]. However,
the results of our meta-analysis do not support a beneficial role of neither omega-3 nor resveratrol on
LF in human populations.
The qualitative assessment of the 12 RCTs suggested that catechins, some probiotics, and carnitine
may be effective in reducing LF. Catechins are known to reduce oxidative stress and the risk of T2DM
in women [47] but its modulating effect on hepatic energy and lipid metabolism remain ill-defined [48].
Compared to the control condition, Lactobacillus [34] and Bifidobacterium spp. [35] showed a trend
towards greater decrease in LF in NASH patients when compared to dietary advice alone. Underlying
mechanisms of LF reduction by a change in the intestinal microbiota may involve the reduction of
host fatty acid absorption and beneficial effects on energy homeostasis inducing weight loss [34,49,50].
A reduction in LF could however also be due to the prebiotic component included in the synbiotic,
as the composite used does not allow to tease out the actual cause of LF reduction [34]. Positive effects
of carnitine, an amino acid derivative transporting free fatty acid into mitochondria for beta-oxidation,
have been linked with improved beta-oxidation, thereby diminishing lipid accumulation [41,51].
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The qualitatively summarized eight RCTs which did not find a significant effect on steatosis
studied vitamin D, nicotinamide riboside, resistant starch, Lactobacillus spp., Bifidobacterium animalis,
and Cordyceps militaris. Benefits of vitamin D and nicotinamide riboside on LF were mainly suggested
by experimental data showing an insulin-sensitizing effect [52,53]. Similarly, insulin resistance was
shown to be improved by Cordyceps militaris in animal studies [54]. With respect to resistant starch,
an insulin-sensitizing effect was also observed humans [55].
Although some DS were shown to reduce LF, the magnitude of the % fat reduction was consistently
less than 5% which is inferior to the effects reported by lifestyle measures such as exercise and calorie
restriction that achieve LF reductions of 25–50% over similar time periods [56,57]. This suggests that a
negative energy balance is the driving force in reducing LF highlighting that well-designed lifestyle
management programs still remains more effective in reducing liver fat than DS. Although preclinical
studies have shown promising effects, most of these have not been translatable into clinical outcomes.
Of note, lack of consistency between preclinical and clinical research further emphasizes the importance
of good practices for DS studies in the preclinical setting, including optimized use of in vitro, in vivo
and in silico models [58].
4.1. Strengths and Limitations of Current Systematic Review
To our knowledge, this is the first systematic review and meta-analysis that analyzes the role
of DS on LF in RCTs using reliable quantitative imaging methods. This review was conducted in
accordance with the Cochrane guidelines [17] and we used the Cochrane risk of bias tool [19] to
rate the quality of the evidence. In order to reduce the risk of publication bias, a highly sensitive
search strategy was created, and additional resources were searched including ClinicalTrials.gov.
Furthermore, our research question is succinct and precise, focused only on liver fat changes, and only
with the use of tomographic imaging.
Nevertheless, we acknowledge a number of limitations: The overall risk of bias in the included
RCTs was relatively high. Limitations in the study design included incomplete description of study
populations (particularly with respect to diagnosing NAFLD and impaired glucose homeostasis)
and background diet and activity level during the intervention and control period. Additionally,
standardization of feeding and activity condition prior to the measuring of LF, which is known to
substantially affect measured values [59], was only specified in a minority of trials. With respect to the
study interventions, there was a high level of heterogeneity between studies assessing the same DS,
only allowing for two DS types to be meta-analyzed. This heterogeneity was caused by differences in
DS regimens (dose and duration), design of comparators, study populations, and outcome assessment
methods. In line with the sex-dependence of NAFLD prevalence, there was a male predominance in
the study population which may limit generalizability of findings to females. The two meta-analyses
that were feasible only included four RCTs and the number of patients in each RCT was relatively low,
where all except for two RCTs [20,23] involved less than 100 participants. Therefore, the results should
be interpreted with caution and were not amenable for subset analysis.
4.2. Implications for Clinical Practice and Future Research
Our findings may provide useful guidance for clinicians counselling patients with NAFLD or at
risk for developing it. In agreement with our findings, the recently published 2019 European Society
for Clinical Nutrition and Metabolism (ESPEN) guidelines on nutritional management of liver diseases
state until further data regarding their efficacy are available, DS cannot be recommended to treat
NAFLD [8].
Of note, the present work only assessed the effect of DS on fatty change which is not necessarily
correlated with advancement of fibrosis, and important risk factors for cardiovascular disease and
mortality [60,61]. Thus, an important implication for future trials may be to assess the effect of DS
on both LF and fibrosis. Novel magnetic resonance protocols combining PDFF measurement and
elastography may open new avenues in this respect.
Nutrients 2020, 12, 2302 11 of 14
Insights provided by this work propose the following further directions to improve the evidence
of DS trials in the field: (i) adequate sample size and length of study intervention; (ii) homogeneous,
well-characterized and gender-balanced study populations; (iii) selection of appropriate outcomes and
measurement techniques.
Ongoing RCTs exploring DS on LF and other features of NAFLD support the interest in the topic
(ClinicalTrials.gov identifiers: NCT03513523, NCT03914495, NCT02568605) and may soon expand
available evidence with additional data.
5. Conclusions
In conclusion, the present work does not support the use of DS to reduce LF across various
obese and overweight patients with different degrees of comorbidities. Future clinical trials assessing
efficacy of DS to reduce LF should be based on high-quality preclinical research and adopt rigorous
experimental designs using homogenous and well-characterized populations, comparison to placebo
and reliable quantitative imaging methods.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/8/2302/s1,
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